Hidroxocobalamina Basi (Hydroxocobalamin)

Hydroxocobalamin Basi is indicated for several clinical situations where vitamin B12 activity is required to restore normal metabolic processes and to treat toxic exposures.

• Treatment of documented vitamin B12 (cobalamin) deficiency.
• Management of cobalamin deficiency anemia.
• Prevention or correction of deficiency in patients with malabsorption, such as pernicious anemia or gastrointestinal surgery.
• Adjunct therapy for cyanide poisoning, where hydroxylcobalamin binds cyanide to form cyanocobalamin.
• Support of normal neurological function in individuals with low B12 levels.
• Correction of elevated homocysteine concentrations associated with B12 deficiency.

• Hydroxocobalamin acts as a cofactor for the enzymes methionine synthase and methylmalonyl‑CoA mutase. By donating a methyl group, it enables conversion of homocysteine to methionine and facilitates the metabolism of odd‑chain fatty acids and amino acids, supporting DNA synthesis and red blood cell formation. In cyanide poisoning, the cobalt atom binds cyanide, forming the non‑toxic cyanocobalamin complex that can be excreted.

Adverse reactions to intramuscular hydroxocobalamin are generally uncommon but may occur.

Common

• Injection site pain, redness, or swelling that usually resolves within a few days.
• Transient headache or dizziness occurring shortly after administration.
• Mild nausea, abdominal discomfort, or gastrointestinal upset.
• Mild flushing or a sensation of warmth at the injection site.
• Temporary increase in serum potassium levels that is typically self‑limited.

Serious

• Severe allergic reaction (anaphylaxis) with rash, itching, swelling of the face, throat, or airway, requiring immediate medical attention.
• Acute hemolytic anemia in patients with underlying enzyme deficiencies, presenting with fatigue and dark urine.
• Sudden drop in blood pressure (hypotension) or cardiovascular instability, potentially leading to fainting.
• Seizures or other neurological symptoms in individuals with pre‑existing central nervous system disorders.
• Renal impairment due to precipitation of cyanocobalamin complexes, especially in patients with pre‑existing kidney disease.

When prescribing or administering hydroxocobalamin, clinicians should consider several precautionary measures to ensure safe use.

• Assess for known hypersensitivity to cobalamin compounds before injection.
• Use caution in patients with renal impairment, as reduced clearance may increase risk of cyanocobalamin accumulation.
• Monitor serum potassium and homocysteine levels in individuals receiving repeated doses.
• Evaluate for underlying enzyme deficiencies (e.g., methylmalonic acidemia) that could predispose to hemolysis.
• Consider pregnancy and lactation status; data are limited, so benefits should outweigh potential risks.
• Avoid intramuscular injection into areas with poor blood supply to reduce local adverse reactions.

Hydroxocobalamin may interact with other medicines or substances; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Avoid

• Avoid concurrent use of high‑dose nitrite or nitrate drugs, which can impair conversion of hydroxocobalamin to its active form.
• Avoid simultaneous administration with other cobalamin products, which may cause excess vitamin B12 levels.

Use with caution

• Use with caution when combined with diuretics that affect potassium balance, due to potential transient hyperkalemia.
• Use with caution in patients receiving chemotherapy agents such as methotrexate, as vitamin B12 status can influence drug toxicity.
• Use with caution in individuals on antihypertensive drugs, since sudden blood pressure changes have been reported.
• Use with caution in renal‑impaired patients taking nephrotoxic drugs, as accumulation of cyanocobalamin complexes may occur.